Victory Capital Management Inc. Grows Position in Revvity, Inc. (NYSE:RVTY)

Victory Capital Management Inc. increased its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 17.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,250 shares of the company's stock after purchasing an additional 10,390 shares during the period. Victory Capital Management Inc. owned 0.06% of Revvity worth $7,841,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RVTY. Empirical Finance LLC grew its stake in shares of Revvity by 2.0% in the third quarter. Empirical Finance LLC now owns 4,237 shares of the company's stock worth $541,000 after acquiring an additional 85 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Revvity by 2.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,214 shares of the company's stock worth $470,000 after acquiring an additional 100 shares during the last quarter. HB Wealth Management LLC grew its stake in shares of Revvity by 4.6% in the fourth quarter. HB Wealth Management LLC now owns 2,380 shares of the company's stock worth $266,000 after acquiring an additional 104 shares during the last quarter. Westside Investment Management Inc. boosted its position in shares of Revvity by 0.8% during the fourth quarter. Westside Investment Management Inc. now owns 14,363 shares of the company's stock valued at $1,603,000 after buying an additional 108 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in shares of Revvity by 5.1% during the third quarter. Coldstream Capital Management Inc. now owns 2,247 shares of the company's stock valued at $286,000 after buying an additional 110 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Revvity Stock Performance

Shares of NYSE RVTY traded down $0.67 during trading on Tuesday, hitting $112.55. The company had a trading volume of 965,569 shares, compared to its average volume of 845,286. The stock has a 50 day simple moving average of $116.97 and a 200 day simple moving average of $117.86. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. Revvity, Inc. has a 12 month low of $97.32 and a 12 month high of $129.50. The firm has a market capitalization of $13.52 billion, a P/E ratio of 50.93, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the prior year, the company earned $1.25 EPS. As a group, analysts anticipate that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.25%. The ex-dividend date is Thursday, April 17th. Revvity's dividend payout ratio (DPR) is currently 12.67%.

Insider Transactions at Revvity

In related news, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the sale, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This represents a 31.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Raymond James reaffirmed an "outperform" rating and set a $145.00 price objective (up from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Sanford C. Bernstein cut Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective on the stock. in a research report on Friday, January 10th. KeyCorp increased their price objective on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Barclays increased their price objective on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, Bank of America raised Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price objective on the stock in a research report on Friday, December 13th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $136.25.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.